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Abstract 
 Ammonia is diffused and transported across all plasma membranes. This entails 
that hyperammonemia leads to an increase in ammonia in all organs and tissues. It is 
known that the toxic ramifications of ammonia primarily touch the brain and cause 
neurological impairment. However, the deleterious effects of ammonia are not specific to 
the brain, as the direct effect of increased ammonia (change in pH, membrane potential, 
metabolism) can occur in any type of cell. Therefore, in the setting of chronic liver 
disease where multi-organ dysfunction is common, the role of ammonia is challenged. 
This review provides insights and evidence that increased ammonia can disturb many 
organ and cell types and hence lead to dysfunction.     
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
3 
 
Effect of ammonia on cell function 
Ammonia is used for a number of different metabolic reactions (including the 
synthesis of non-essential amino acids). However it is primarily a waste product of cellular 
metabolism and due to its harmful properties at higher concentrations, ammonia is quickly 
detoxified and transformed into less toxic compounds (Cooper and Plum, 1987; 
Butterworth, 2002). Under physiological conditions, blood levels of ammonia (in systemic 
circulation) are carefully maintained at concentrations <50µM in adults, 50-75µM in term 
neonates and 50-150µM in preterm neonates (Braissant et al., 2013). Here, the liver plays 
a vital role in regulating the levels of ammonia via the production of urea (a cycle of 
enzymes which together are solely found in the liver). Ammonia is also removed in 
extrahepatic organs, including the muscle and brain (astrocytes), through the amidation of 
glutamate to glutamine via the enzyme glutamine synthesis (GS) (Cooper and Plum, 1987).
  
The main source of ammonia generation occurs in the intestines; from lysis of 
blood-borne urea and also from protein digestion/deamination by urease-positive bacteria 
and microbial deaminase (Jones et al., 1969). A large amount of metabolically-generated 
ammonia is absorbed into the blood and via the portal vein is detoxified through the liver 
(Cooper and Plum, 1987; Brusilow et al., 2010). The concentration of ammonia in portal 
vein can be 5-10x higher than in the systemic circulation (Abdo, 2006) and during 
conditions of liver disease or failure, ammonia is poorly removed (due to impaired 
ureagenesis from hepatocellular dysfunction and portosystemic shunting) and is liberated 
into the systemic circulation and exposed to all organs (Rovira et al., 2008). Glutaminase, 
an enzyme which generates glutamate and ammonia from glutamine and which is found in 
the intestine, kidney and brain (neurons), also plays a contributing role to the development 
of hyperammonemia. Diseases causing hyperammonemia include acute liver failure 
(ALF), chronic liver disease (CLD) and portal-systemic shunting (Felipo and Butterworth, 
2002). Hyperammonemia also develops in children with inborn errors of the urea cycle and 
tend to present with higher blood ammonia concentrations (up to 5 mM) compared to 
acquired causes (such ALF and CLD) which usually result in hyperammonemia levels 
between 0.2-1 mM (Ratnakumari et al., 1992; Matkowskyj et al., 1999; Butterworth, 2002; 
Lichter-Konecki et al., 2008).  
Ammonia in solution (i.e blood) is present as NH3 and NH4
+ with the ratio 
NH3/NH4
+ depending on the pH as defined by the Henderson-Hasselbach equation. Under 
physiological conditions with a blood pH of 7.4, more than 98% of ammonia is in NH4
+ 
form (Bromberg et al., 1960). Both forms affect pH, electrolytic, acid-base and ion 
equilibrium. NH3 is a weak base in gaseous form and uncharged, therefore lipid soluble 
and capable to cross cell membranes through diffusion. Conversely, NH4
+ is a weak acid, 
water soluble and because of its ionic properties crosses cell membranes at a less rapid rate 
through various transport channels (Bosoi and Rose, 2009). Due to almost identical 
hydration radius with K+ (Kikeri et al., 1989), NH4
+ can substitute K+ in its channels and 
transporters (ATPase transporters Na+/K+ and H+/K+ (Moser, 1987) and Na+/K+/Cl− co-
transporters (Kelly et al., 2009)). This NH4
+ substitution in K+ channels mediates 
membrane depolarization in vitro (Allert et al., 1998; Norenberg, 1998), but putatively not 
in situ (Rangroo Thrane et al., 2013). Ammonia can also enter cells through aquaporin-8 
channel (Liu et al., 2006; Saparov et al., 2007) and ammonia specific transporters (human 
non-erythroid Rhesus glycoprotein B and C (Bakouh et al., 2006)). There is also growing 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
4 
 
evidence that ammonia can cross blood-brain barrier (BBB) preferentially by active 
transport through ion transporters rather than diffusion (Sørensen, 2013) and it has been 
shown that ammonia invade paracellular and transcellular passage of different molecules 
across the BBB (Braissant, 2012; Skowronska and Albrecht, 2012), as well as to a lesser 
extent by direct diffusion of NH3. Furthermore, ammonia primarily enters astrocytes lining 
the BBB as these cells have the highest affinity for potassium (Marcaggi et al., 2004; Bosoi 
and Rose, 2009; Rangroo Thrane et al., 2013). 
Ammonia alters both intracellular and extracellular pH and can cause intracellular 
acidification as well as alkalisation, all depending on ammonium concentration, pH and 
rate of NH3 vs. NH4
+ transport through the cell membrane (Norenberg, 1998; Bosoi and 
Rose, 2009; Rangroo Thrane et al., 2013). Ammonia has also be shown to cause a rise in 
intracellular Ca2+ primarily due to cytosolic alkalinisation in vitro (Rose et al., 2005) and 
through less well characterized mechanisms lead to increased intracellular Ca2+ signalling 
in vivo (Rangroo Thrane et al., 2013). Ammonia-induced changes in pH, membrane 
potential as well as alterations in cellular metabolism negatively impacts cell function by 
influencing signalling transduction pathways, activities of many enzymes, alternation in 
protein phosphorylation and the state of various other ion channels and transporters (Busa 
and Nuccitelli, 1984; Norenberg, 1998; Cudalbu, 2013). Furthermore, increased ammonia 
metabolism will lead to metabolic disturbances. NH4
+ detoxification by converting α-
ketoglutarate to glutamate and glutamate to glutamine leads to α-ketoglutarate depletion 
consequently stressing the tricarboxylic acid cycle (Braissant et al., 2013). 
Elevated concentrations of ammonia have been shown to generate free radicals 
(Kosenko et al., 1997; Murthy et al., 2001; Sinke et al., 2008; Norenberg et al., 2009) and 
leads to excessive production of nitric oxide (NO) by stimulating the citrulline-NO cycle 
(Braissant et al., 1999; Bachmann et al., 2004; Zielinska et al., 2011). Alteration of NO 
synthesis and oxidative stress can result in the induction of mitochondrial permeability 
transition (MPT) (Halestrap et al., 1997; Kowaltowski et al., 2001), alterations of BBB 
permeability (in some disease models) (Rangroo Thrane et al., 2012; Skowronska and 
Albrecht, 2012; Braissant et al., 2013) and activation of MAPKs (Cagnon and Braissant, 
2009). Ammonia also activates the transcription factor NF-κB, involved in immune and 
inflammatory reactions, (Sinke et al., 2008) probably as a result of increased oxidative 
stress, activated MAPKs and induced MPT (Marchetti et al., 1996; Bowie and O’Neill, 
2000; Kyriakis and Avruch, 2001). 
In addition, liver function impairment independently provokes deviation from 
physiological values of over 20 different compounds in the circulation (Zieve, 1987) as 
well as many other factors including inflammation and oxidative stress. In some cases it 
can be very difficult to distinguish the independent effect of ammonia and therefore other 
factors (synergistic effects) should be considered (Butterworth, 2008; Bosoi et al., 2012; 
DeMorrow, 2013; Aldridge et al., 2015). 
 
The effects of ammonia toxicity on the brain 
In the brain, ammonia homeostasis is tightly regulated and linked to recycling of 
the major excitatory and inhibitory neurotransmitters glutamate and γ-aminobutyric acid 
(GABA) (Paulsen et al., 1987; Bak et al., 2006; Hertz and Kala, 2007). Interestingly, GS 
in astrocytes has a higher affinity for ammonia than glutamate, indicating that the removal 
of ammonia may be more important than that of the principle excitatory neurotransmitter 
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(Waniewski, 1992). Ammonia neurotoxicity is a phenomenon that affects all cerebrate 
species, from fish to humans (Ip and Chew, 2010). Gross neurological dysfunction occurs 
in conditions that lead to excess blood and therefore brain ammonia, including 
encephalopathy, seizures, ataxia and coma (Butterworth, 2002).  
Toxic levels of ammonia and alterations in pH, electrolyte disturbances, membrane 
potential depolarization, are thought to lead to neurological dysfunction primarily by 
causing cellular swelling accompanied by brain edema and metabolic dysfunction (Bosoi 
and Rose, 2009). Ammonia is likely to be particularly toxic to astrocytes as they are the 
only cells that possess the enzyme GS responsible for detoxifying ammonia in the brain 
through condensation with glutamate (Martinez-Hernandez et al., 1977; Hertz and Zielke, 
2004). In fact, astrocytes are likely to take up four times more ammonia than any other cell 
type in the brain (Cooper et al., 1979). Moreover, one of the early pathophysiological 
findings in HE was the presence of brain edema, and specifically astrocyte swelling in 
histological specimens and in vitro. Astrocyte swelling is also found in the later stages of 
HE in most animal models of liver failure and hyperammonemia (Gregorios et al., 1985a, 
1985b; Ganz et al., 1989; Willard-Mack et al., 1996; Tanigami et al., 2005; Cagnon and 
Braissant, 2007; Jayakumar et al., 2008; Butterworth et al., 2009; Rangroo Thrane et al., 
2012; Rao et al., 2014). These findings correlated with increased ammonia and glutamine 
levels and it was therefore hypothesized that ammonia exerted its neurotoxic effects by 
accumulation of glutamine causing astrocyte swelling (termed osmotic gliopathy). 
However, astrocyte swelling in the context of ammonia neurotoxicity had until recently not 
been directly visualized in living tissue. In a hyperacute model of isolated 
hyperammonemia (urea cycle deficiency), doses of ammonia sufficient to cause stupor, 
seizures and ataxia did not induce astrocyte swelling in vivo (Rangroo Thrane et al., 2013). 
Additionally, deleting the main astrocyte water channel, aquaporin 4 (AQP4), did not affect 
disease outcome. However, lethal doses of parenteral ammonia did cause brain swelling in 
vivo and astrocyte swelling in situ (Rangroo Thrane et al., 2013), and AQP4 deletion does 
appear to protect against brain edema in the context of HE (Rao et al., 2014). Therefore, 
although brain edema is a prominent and widely acknowledged clinical feature of the later 
stages of HE and contributes to mortality, it does not explain all the neurotoxic effects of 
ammonia (Joshi et al., 2014). 
Several alternate and/or synergistic neurotoxic effects of ammonia on astrocytes 
have previously been studied. These include impairment of oxidative metabolism; with a 
consequent increase glycolysis (mainly in astrocytes) and dangerously elevated brain 
lactate levels (Ott et al., 2005; Dam et al., 2013; Bosoi et al., 2014). Ammonia itself is also 
widely known to cause pH changes that might affect cellular function due to its ability to 
act both as a weak acid and base. However, in vivo studies using liver failure models, pH 
electrodes and NMR show either an overall increase of intracellular pH ranging from 0.1 
to 0.4 or no change (Fitzpatrick et al., 1989; Swain et al., 1991; Kanamori and Ross, 1997; 
Rangroo Thrane et al., 2013). The main limitations of these studies are the indirect 
measures of pH and the inability to accurately distinguish intra- from extracellular pH. 
Ammonia has also recently been shown to impair astrocytic calcium signaling in vivo, 
which is closely linked to many astrocytic housekeeping functions, such as K+ homeostasis 
(Rose et al., 2005; Wang et al., 2012; Rangroo Thrane et al., 2013). Additionally, ammonia 
appears to directly disrupt astrocyte potassium buffering in vivo by competing for transport 
via either the Na+-K+-ATPase, K+ channels or Na+-K+-Cl- cotransporters (Alger and Nicoll, 
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1983; Brookes and Turner, 1993; Marcaggi et al., 2004; Rangroo Thrane et al., 2013). An 
acute increase in both extracellular ammonia and potassium has been shown to cause a 
depolarizing shift in the GABA equilibrium potential (EGABA), thus leading to decreased 
neuronal inhibition in vivo (Lux, 1971; Benjamin et al., 1978; Rangroo Thrane et al., 2013). 
This effect likely explains the seizure phenotype seen in models of urea cycle deficiencies 
(Cagnon and Braissant, 2007). Additionally, ammonia has been found to contribute to 
seizure generation in epileptic children with normal liver function (Yamamoto et al., 2013), 
and reactive gliosis seen in temporal lobe epilepsy may induce seizures via an almost 
identical mechanism (Robel et al., 2015).  
More recently, a contribution of other cell types than astrocytes to the 
pathophysiology of HE and hyperammonemia has gained greater recognition (Butterworth, 
2011). Microglia are the resident immune cells in the brain, and known to survey the brain 
microenvironment for signs of pathogens and inflammation with their fine processes 
(Nimmerjahn, 2005). When activated, they become more amoeboid in structure, 
facilitating phagocytosis and release multiple pro-inflammatory mediators (Ransohoff and 
Cardona, 2010). In the late stages of HE, histological studies have shown that microglia 
are activated in animal models of CLD, ALF, portocaval shunting and in post mortem 
tissue from patients (Jiang et al., 2009a, 2009b; Rodrigo et al., 2010; Agusti et al., 2011; 
Zemtsova et al., 2011). Several studies indicate that this microglial activation is correlated 
with BBB opening and brain edema (Jiang et al., 2009a, 2009b; Rangroo Thrane et al., 
2012). However, microglia were not found to be activated in a model of portal vein ligation 
(Brück et al., 2011) and acute isolated hyperammonemic mice (Rangroo Thrane et al., 
2012). It is therefore possible that the microglial activation is not a response to ammonia 
per se, but rather relates to other secondary features of ammonia neurotoxicity such as 
oxidative stress, cellar distress signals or BBB opening. Finally, ammonia likely has a 
range of direct and indirect effects on neurons, pericytes and endothelial cells, which have 
been more extensively reviewed in other publications (Szerb and Butterworth, 1992; 
Rodrigo and Felipo, 2006; Leke et al., 2011; Thumburu et al., 2012; Shaik et al., 2013). 
In summary, the best described deleterious effects of ammonia are associated with 
the brain as the brain is exquisitely sensitive to even minor increases in the blood ammonia 
levels. Within the brain, although elevated levels of ammonia are noxious for astrocytes, it 
also has deleterious effects on all cells of the central nervous system (Figure 1). However, 
can ammonia be considered solely as a neurotoxin? The toxic effects of ammonia are not 
specific to the brain and there is evidence depicting ammonia toxicity is diffused to 
organs/tissues and cells in the body. 
 
The effects of ammonia toxicity on muscle 
Sarcopenia or loss of skeletal muscle mass is the most frequent and potentially 
reversible complication in cirrhosis (Dasarathy, 2012). Despite the universally recognized 
adverse consequences on survival, development of other complications in cirrhosis, quality 
of life, and post liver transplant outcomes, there are no effective therapies primarily 
because the mechanisms of sarcopenia are incompletely understood (Dasarathy, 2012). In 
addition to the lower muscle mass, muscle strength is also reduced in cirrhosis and 
contributes to adverse clinical outcomes (Jones et al., 2012). Recent evidence strongly 
suggests that hyperammonemia is a mediator of the liver muscle axis (Qiu et al., 2013). It 
is also important to emphasize that identifying ammonia as a mediator of the liver-muscle 
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axis is especially relevant because effective therapeutic strategies to reverse 
hyperammonemia are available (Phongsamran et al., 2010).  
Previous studies have reported an increased muscle uptake of ammonia in cirrhosis 
results in glutamine synthesis that is released into the circulation (Ganda and Ruderman, 
1976; Lockwood et al., 1979; Holecek, 2013). Muscle uptake and metabolism of ammonia 
is however not a benign process since a number of molecular and metabolic perturbations 
have been reported during muscle hyperammonemia (Qiu et al., 2012, 2013). The 
consequences of increased muscle uptake of ammonia include both a reduction in muscle 
mass and muscle strength (Shanely and Coast, 2002; Qiu et al., 2012). Both metabolic and 
molecular responses to muscle hyperammonemia contribute to muscle loss and weakness. 
 
Metabolic perturbations during hyperammonemia 
Since ureagenesis in the liver is impaired and muscle cannot generate urea, 
ammonia removal by the muscle utilizes a cataplerotic conversion of α-ketoglutarate, a 
critical tricarboxylic acid cycle intermediate to generate glutamate and glutamine thereby 
removing 2 moles of ammonia for each mole of α-ketoglutarate. However, the conversion 
of α-ketoglutarate to glutamate, the first step in this reaction is catalyzed by glutamate 
dehydrogenase that has a low affinity for ammonia promoting the anaplerotic direction 
generating α-ketoglutarate from glutamate rather than glutamate from α-ketoglutarate 
(Wootton, 1983). Under most physiological conditions, since muscle ammonia 
concentrations do not reach the Km of this enzyme (~1 mM), there is not net cataplerosis 
of α-ketoglutarate. In cirrhosis, we have consistently reported tissue concentrations of 
ammonia ~4 mM that favors cataplerosis of α-ketoglutarate to glutamate. This is consistent 
with our observations of lower TCA cycle intermediates in the skeletal muscle during 
hyperammonemia. Impaired muscle mitochondrial function and ATP generation 
accompany lower TCA cycle intermediates. These observations provide a mechanistic 
basis for the previously reported impaired skeletal muscle mitochondrial electron chain 
complex function in cirrhosis. Reduction in muscle ATP also contributes to lower protein 
synthesis since peptide chain elongation is a high energy-requiring step. Increased 
autophagy is a homeostatic response and provides amino acids for anaplerotic reactions. 
Additionally, reduction in ATP generation also contributes to skeletal muscle contractile 
dysfunction in cirrhosis.  
 
Skeletal muscle molecular abnormalities during hyperammonemia 
In addition to skeletal muscle metabolic derangements, ammonia also results in 
impaired skeletal muscle protein synthesis and increased autophagy. The principal pathway 
of impaired protein synthesis involves the canonical Akt/mTOR mediated regulation of cap 
dependent protein synthesis. Myostatin, a TGF-β superfamily member is a potent inhibitor 
of muscle protein synthesis and inhibits mTOR activation either via an Akt dependent or 
independent mechanism. Consistently, blocking myostatin increases muscle mass and 
protein synthesis (Dasarathy et al., 2011).  
Hyperammonemia also increases muscle autophagy that in combination with 
impaired protein synthesis results in loss of muscle mass (Qiu et al., 2012). Both impaired 
mTOR signaling and activation of AMPK contribute to the increased autophagy. Ammonia 
also increases protein nitration either directly or by increased generation of reactive oxygen 
and nitrogen species and autophagy has been shown to contribute to clearance of post 
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translationally modified muscle proteins (unpublished data). Posttranslational modification 
of proteins can potentially impair the actomyosin interaction during muscle contraction and 
result in impaired muscle contractile function.  
 
Therapeutic relevance of muscle hyperammonemia. 
The metabolic and molecular data support our belief that hyperammonemia induces 
a state of anabolic resistance because previous strategies to increase muscle mass by 
nutritional and hormonal strategies have not been consistently been effective (Tsien et al., 
2012). Our studies using an integrated molecular-metabolic approach have shown the 
interaction between signaling abnormalities and metabolic demands during muscle 
hyperammonemia lay the foundation for novel mechanistic therapeutic strategies.  Our 
model supports the use of long term ammonia lowering, myostatin antagonism, stimulating 
muscle mTOR, and providing anaplerotic substrates to reverse the adverse consequences 
of hyperammonemia. Mitochondrial dysfunction and generation of mitochondrial reactive 
oxygen species and resultant oxidative stress responses are also potential targets to reverse 
the adverse skeletal muscle responses of hyperammonemia (unpublished data).  
Consistently, myostatin blocking using either follistatin or myostatin knockout in 
mice have been reported to be effective in reversing hyperammonemia mediated impaired 
muscle protein synthesis and contractile function (Dasarathy et al., 2011; Qiu et al., 2012, 
2013). Even though ammonia lowering strategies have been effective in reversing 
encephalopathy (Phongsamran et al., 2010), there is little data on the impact on the skeletal 
muscle. One potential reason is that skeletal muscle contractile proteins are long lived and 
long-term ammonia lowering strategies may be necessary to result in clinically relevant 
responses.   
Interestingly, recent studies have reported that leucine is an anaplerotic substrate 
generating of α-ketoglutarate (Schachter and Sang, 1997). Additionally, leucine stimulates 
mTOR directly providing a compelling therapeutic rationale for the use of leucine to 
reverse muscle hyperammonemia and its consequences. Consistently, human and animal 
studies in cirrhosis have shown that high doses of leucine have a beneficial effect in 
reversing impaired skeletal muscle protein synthesis (Tsien et al., 2015). The use of cell 
permeable esters of α-ketoglutarate also holds promise as a strategy to increase muscle 
ammonia disposal. Other potential interventions include enhanced non-hepatic ammonia 
disposal via non-toxic pathways, antioxidants and mitochondrial stabilizers need to be 
evaluated. On final note, even though hyperammonemia is a mediator of the liver muscle 
axis, plasma ammonia is elevated in patients with chronic pulmonary disease, severe heart 
failure and cancers all of which are accompanied by significant skeletal muscle loss 
(Bessman and Evans, 1955; Chance et al., 1988; Calvert et al., 2010). Therefore, the current 
approach has broad therapeutic potential across multiple organ dysfunctions.  
In conclusion, hyperammonemia occurs in a number of chronic diseases and 
potentially contributes to sarcopenia and adverse clinical outcomes. Recent advances in 
our understanding of the molecular and metabolic responses to hyperammonemia in the 
skeletal muscle provide a mechanistic basis for developing effective therapies (Figure 2).  
 
The effect of ammonia on other organs 
Kidney 
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It has been shown in healthy volunteers that following exposure to 
hyperammonemia, the kidneys take up net ammonia from the systemic circulation (Owen 
et al., 1961). However, it has been demonstrated in both cirrhotic patients and 
hyperammonemic rodents, that the kidney becomes a primary source of ammonia (Owen 
et al., 1961; Olde Damink et al., 2003; Ytrebø et al., 2006). Elevated systemic ammonia 
concentrations following CLD may directly interact with glomerular cells and contribute 
to glomerular injury (Ling et al., 1998). Hyperammonemia also plays a crucial role in 
tubulointestinal fibrosis (Ling et al., 1998). Gordon et al. displayed evidence ammonia has 
the capacity to promote tubulointestinal injury due to the interaction of ammonia with the 
third component of complement, a potent stimulus to the production of reactive oxygen 
species by polymorphonuclear leukocytes and monocytes (Gordon et al., 1985). In this 
context, Nath et al. demonstrated that hyperammonemia induces the progression of renal 
injury, not only through complement cascade, but also through the stimulatory effects of 
ammonia on renal growth (Nath et al., 1991). In fact, oxidative stress can also cause renal 
ammoniagenesis which may contribute to progression of renal injury (Dan et al., 2008). By 
contrast, a very recent study by Satpute et al. observed that subacute exposure to 
ammonium acetate in rats induces renal necrosis and tubular degeneration, which were not 
correlated with either oxidative or biochemical changes (Satpute et al., 2014). Indeed, it is 
apparent that exposure of neutrophils to ammonia impair phagocytosis and promotes 
increased reactive oxygen species generation that results in oxidative stress at infection 
sites and collateral damage to host tissue (Shawcross et al., 2008). 
During ALF, kidneys are capable of continuous ammonia release into the systemic 
circulation (Ytrebø et al., 2006). A recent study by Cauli et al. demonstrated in rats with 
acute liver failure that activation of N-methyl D aspartate (NMDA) receptors contribute to 
hyperammonemia-induced encephalopathy and kidney damage. Moreover, blocking 
NMDA receptors with MK-801 improved ammonia elimination and glomerular filtration 
rate and delayed kidney damage (Cauli et al., 2014), confirming the deleterious effects of 
high ammonia concentration in kidneys. Furthermore, ammonia administered to rats lead 
to disturbances in renal sodium handling that was preceded by activation of kidney mitogen 
activated protein kinases/extracellular signal regulated kinases (MAPK/ERKs) signaling 
pathways, and consequently renal injury (Bento et al., 2005). It has been shown that 
kidneys perfused with ammonium salts results in cortical and tubular necrosis, with 
necrotic kidneys demonstrating depressed creatinine clearance (Orvell and Wesson, 1976). 
Ammonia exposure also inhibits tubular cell proliferation in primary rabbit proximal 
tubular epithelial cells, therefore affecting cell replication (Rabkin et al., 1993). 
Collectively, these findings suggest that hyperammonemia does lead to impaired kidney 
function and sustaining kidney injury. 
 
Liver 
As indicated above, whilst astrocytes are major effectors of brain injury in liver 
failure, it is of interest that they share many similar markers of activation with hepatic 
stellate cells (HSC), which are implicated in the development of liver fibrosis and also the 
increase in intra-hepatic resistance with evolving liver injury (Rockey, 1997). Indeed, HSC 
contraction is one of the mechanisms that is central to the development of portal 
hypertension, a serious haemodynamic consequence of cirrhosis. HSC have been shown to 
possess GS (Bode et al., 1998) and recent data shows that in rodent models of cirrhosis, 
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high ammonia concentrations are associated with increased HSC contraction and raised 
portal pressure and conversely, lowering ammonia decreases HSC activation and 
ameliorates portal hypertension (Jalan et al., 2016).  
In addition to the impact on HSC contraction, elevated ammonia has been shown 
to promote liver injury through up-regulation of toll-like receptor genes, generation of 
oxidative stress through activation of resident macrophages and neutrophils and activation 
of NFκB and iNOS. In addition, ammonia promotes increased hepatocyte apoptosis and 
changes in cell cycle with higher cyclin D1, thereby further promoting liver injury as liver 
disease evolves (Jia et al., 2014). It is possible that impaired urea cycle metabolism and 
reduced liver clearance of ammonia primes the liver and other organs to the impact of acute 
inflammation and further oxidative stress, as occurs in conditions such as acute-on-chronic 
liver failure, though this assertion requires mechanistic evaluation. 
 
Lung 
Several studies have discussed the detrimental effects of ammonia on lungs 
following exposure to ammonia gas. Ammonia inhalation also can damage respiratory tract 
leading to acute lung injury and pulmonary edema, which can ultimately lead to death 
(Ortiz-Pujols et al., 2014). Furthermore, ammonia inhalation to rats causes increased 
oxidative stress, decreased antioxidant enzymes and acute lung injury which was 
attenuated following α-ketoglutarate treatment (Ali et al., 2012). Ammonia induced acute 
lung injury have also been shown in rabbits associated with an elevated airway pressure 
and a decrease in PaO2 (Sjöblom et al., 1999) and has been shown to induce lung fibrosis 
(Ohnuma-Koyama et al., 2013). Ammonia and enzymatically active urease released from 
parasitic cells of Coccidioides posadasii contribute to host tissue damage and exacerbate 
the severity of coccidioidal lung infections (Mirbod et al., 2002; Mirbod-Donovan et al., 
2005; Wise et al., 2013). In this context, it has been concluded that enzymatically active 
urease is partly responsible for increased extracellular ammonia concentrations at sites of 
lung infection, contributing to both localized host tissue damage and exacerbation of the 
respiratory disease (Lichtenstein et al., 1997). 
 
The effect of ammonia on vascular function  
Chronic hyperammonemia is believed to decrease cGMP formation and thereby 
secondary signaling for NO, one of the main regulators of tonic vasodilatation (Cauli et al., 
2007). Moreover, as previously mentioned, the promotion of reactive oxygen species 
generation by ammonia gives rise to further endothelial dysfunction by decreasing 
expression of dimethylarginine dimethylamino hydrolase (DDAH1), a cytosolic enzyme 
that metabolizes asymmetric dimethylarginine (ADMA), a key endogenous inhibitor of 
NO. High ADMA levels have previously been shown to be associated with impaired 
cerebral perfusion during hyperammonemia (Balasubramaniyan et al., 2012) and also with 
high intrahepatic resistance in advanced liver disease (Mookerjee et al., 2007). Similarly, 
under high oxidative stress conditions, there is increased un-coupling of nitric oxide 
synthase with less NO bioavailability (Xia et al., 1998) and greater nitration of proteins 
with the generation of peroxynitrite and nitrotyrosine, further promoting organ injury. 
Furthermore, important cationic transporters such as the y+ LAT2 system are also 
stimulated by high ammonia levels, resulting in arginine efflux from endothelial cells in 
exchange for glutamine uptake (Zielinska et al., 2011), and thus loss of substrate for nitric 
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oxide synthase to generate NO. Thus at multiple levels, ammonia appears to control 
endothelial function and resistance to vascular flow, whilst also promoting further organ 
injury. It is perhaps, therefore, not surprising that with progression to advanced cirrhosis 
and ascites formation and greater ammonia generation, resistive indices for the middle 
cerebral artery and renal vasculature have been shown to increase, and correlate with 
severity of hyperdynamic circulatory dysfunction as noted through high renin levels 
(Guevara et al., 1998).  
 
Conclusion 
Increases in ammonia can lead to changes in pH, membrane potential (due to 
similar properties of NH4
+ and K+) and cell metabolism. While ammonia 
(hyperammonemia) is unequivocally key in the development of HE, the effects of ammonia 
toxicity are not specific to the brain. It is therefore possible that the deleterious 
consequences of increased ammonia can impinge on other organs and to date, there is 
increasing evidence that ammonia is clearly much more than a neuro-toxin. Evidently the 
brain is more sensitive to ammonia toxicity and recognizing ammonia tolerance/intolerance 
in other organs merits to be further investigated. Better understanding of how increased 
ammonia affects various cells and tissues within the body can help lead to better therapeutic 
strategies for the management of patients with hyperammonemia. 
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Figure 1. Effects of ammonia toxicity in brain. Left, physiological ammonia handling in the 
brain. Right, some of the proposed neurotoxic effects of excess brain ammonia. Glutamate (Glu), 
glutamine synthetase (GS), glutamine (Gln), adenosine triphosphate (ATP), sodium-coupled 
neutral amino acid transporters (SNAT1/2 and 5), glutamate transporter 1 (GLT1), glutaminase 
(Glnase), glutamate and γ-aminobutyric acid (GABA), glutamate receptor (GluR), GABA receptor 
(GABAR), cerebral blood flow (CBF), cerebral metabolic rate of oxygen (CMRO2), cerebral 
metabolic rate of glucose (CMRGlc), GABA reversal potential (EGABA), cytokines (CK).  
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